AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03292861
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
Trial: NCT02252497
Drug: Active comparator : Tranexamic Acid (Exacyl)
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours .
Trial: NCT03292861
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance doses of sirolimus at 12 months post-transplantation
Trial: NCT04089163
Drug: Toca FC (extended-release formulation of flucytosine)
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
Trial: NCT00294632
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting Dose 10 mg By Mouth Daily on Days 1-21
Trial: NCT00294632
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 By Vein Weekly for 4 Weeks
Trial: NCT01890785
Drug: Lisdexamfetamine Dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of a 70 mg capsule on Day 1
Trial: NCT02715466
Drug: Balanced gelatine solution
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelaspan combined with Sterofundin ISO
Trial: NCT04071626
Drug: Ertugliflozin 5 mg
RxNorm normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin 5 mg once a day for 12 weeks
Trial: NCT04580472
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
Trial: NCT01715415
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)
Trial: NCT03736720
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01112683
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
Trial: NCT01754909
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
Trial: NCT01866553
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg capsule BID oral use
Trial: NCT01866553
Drug: Pegylated interferon α-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 - 40 microgram per week for subcutaneous use
Trial: NCT00214500
Drug: migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03170232
Drug: Danirixin 35 mg tablets
RxNorm normalized name: Danirixin
DrugBank: Danirixin (DB11922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
Trial: NCT04495257
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
Trial: NCT04495257
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
Trial: NCT04495257
Drug: APX005M
RxNorm normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX005M 0.3mg/kg intravenously (IV) every 3 weeks
Trial: NCT01439347
Drug: Vincristine Sulfate Liposomes Injection (VSLI)
RxNorm normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
Trial: NCT01439347
Drug: Vincristine Sulfate Injection (VSI)
RxNorm normalized name: vincristine sulfate Injection
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
Trial: NCT02284919
Drug: [18F]ISO-1
RxNorm normalized name: [18F]ISO-1
DrugBank: ISO-1 F-18 (DB14900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]ISO-1 PET/CT scan
Trial: NCT02235909
Drug: Azilsartan Medoxomil Low-dose
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil low-dose (AZM-L) 10 mg
Trial: NCT02235909
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02235909
Drug: Placebo for Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02235909
Drug: Placebo for Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02235909
Drug: Azilsartan Medoxomil Medium-dose (20 mg)
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil medium-dose (AZM-M) 20 mg
Trial: NCT02235909
Drug: Azilsartan Medoxomil High-dose (40 mg)
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil high-dose (AZM-L) 40 mg
Trial: NCT02942355
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole by mouth daily
Trial: NCT02942355
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib by mouth daily days 1-21 every 28 days
Trial: NCT00882700
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00882700
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03774173
Drug: Aramchol
RxNorm normalized name: Aramchol
DrugBank: Aramchol (DB11860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
Trial: NCT03724747
Drug: Darolutamide(BAY1841788)
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
Trial: NCT00883844
Drug: Nucleos(t)ide analogue treatment with a peginterferon add-on strategy
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
Trial: NCT03724968
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be given by vein on day 1 of each cycle.
Trial: NCT03724968
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Relatlimab will be given by vein on day 1 of each 28-day cycle
Trial: NCT03724968
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
Trial: NCT04575025
Drug: Tabrecta tablets
RxNorm normalized name: Tabrecta
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT01390506
Drug: Sodium-selenite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
Trial: NCT01142466
Drug: Interferon beta-1a (Rebif)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
Trial: NCT00080288
Drug: Armodafinil 150 mg/day
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
Trial: NCT02488902
Drug: Tafenoquine 25mg
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 25mg
Trial: NCT02488902
Drug: Tafenoquine 50mg
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 50mg
Trial: NCT02488902
Drug: Tafenoquine 100 mg
RxNorm normalized name: tafenoquine 100 MG
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 100 mg
Trial: NCT02488902
Drug: Tafenoquine 200 mg
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg
Trial: NCT02488902
Drug: Mefloquine 250 mg
RxNorm normalized name: mefloquine 250 mg oral tablet
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine 250 mg
Trial: NCT02979522
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin infusion
Trial: NCT02979522
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinblastine infusion
Trial: NCT02979522
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine infusion
Trial: NCT01246973
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
Trial: NCT03633019
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose rhTPO ih
Trial: NCT01980316
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
Trial: NCT01980316
Drug: non-argatroban treated group
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in control group will receive Unfractionated heparin treatment
Trial: NCT00525564
Drug: Salmeterol diskus inhalation powder
RxNorm normalized name: salmeterol Dry Powder Inhaler
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 micrograms twice a day
Trial: NCT04268784
Drug: DNL343
RxNorm normalized name: DNL343
DrugBank: DNL343 (DB18678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and repeating oral dose(s)
Trial: NCT00044005
Drug: Lurasidone 20 mg
RxNorm normalized name: lurasidone 20 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 20mg oral tablet taken once daily for 6-months
Trial: NCT00044005
Drug: Lurasidone 40 mg
RxNorm normalized name: lurasidone 40 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 40mg oral tablets taken once daily
Trial: NCT00044005
Drug: Lurasidone 80mg
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 80mg oral tablet taken once daily
Trial: NCT02314273
Drug: rhIL-11
RxNorm normalized name: Oprelvekin (rhIL-11)
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
Trial: NCT02100527
Drug: PF-05175157
RxNorm normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
Trial: NCT01664273
Drug: Plasmid AMEP
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur.
Trial: NCT03197571
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (SP-4-2)-diamminedichloroplatinum(II)
Trial: NCT03197571
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Trial: NCT01837420
Drug: VB-201 80mg
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01837420
Drug: VB-201 160mg
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03197571
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Trial: NCT03197571
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3-acid ethyl esters
Trial: NCT00003682
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02218177
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-VEGF treatment for wet age related macular degeneration
Trial: NCT02218177
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-VEGF treatment for wet age related macular degeneration
Trial: NCT01230125
Drug: Mapracorat
RxNorm normalized name: Mapracorat
DrugBank: Mapracorat (DB12041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill study medication into study eye per dosing instructions for 14 days
Trial: NCT00082472
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02598622
Drug: Acetylcarnitine
RxNorm normalized name: Acetylcarnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcarnitine is taken 2 times a day for days 1 through 21.
Trial: NCT00082472
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00814216
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01037101
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of DCS administered 30 minutes before the session
Trial: NCT01127386
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg od, dose reduction according to toxicity
Trial: NCT01127386
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
Trial: NCT04152980
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
Trial: NCT02283177
Drug: crenolanib
RxNorm normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02283177
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02283177
Drug: daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02283177
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02064075
Drug: Lactated Ringer's solution
RxNorm normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
Trial: NCT03724916
Drug: TAK-079
RxNorm normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 subcutaneous injection.
Trial: NCT03724916
Drug: TAK-079 Placebo
RxNorm normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 placebo-matching subcutaneous injection.
Trial: NCT02064075
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
Trial: NCT03197662
Drug: Intranasal Oxytocin (IN-OXT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Trial: NCT00171119
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00830388
Drug: Ketoconazole 2% Foam
RxNorm normalized name: KETOCONAZOLE 2% FOAM,TOP
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
Trial: NCT00388479
Drug: Alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06400251
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01422720
Drug: Eslicarbazepine Acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ESL tablets (800 mg) QD
Trial: NCT00606801
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine 8 mg/day
Trial: NCT04090398
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05158647
Drug: MgSo4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
Trial: NCT03746301
Drug: Rivaroxaban(Xarelto,BAY 59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg, 15mg and 20 mg film-coated tablets